← Oncology Approval Tracker

FDA DECISION ·

Inlexzo

gemcitabine intravesical system · Janssen Biotech

FDA approvalNew formulationNon-muscle-invasive bladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with BCG-unresponsive non-muscle-invasive bladder cancer and carcinoma in situ, with or without papillary tumors.

LAMPGEN ANALYSIS

Why it matters

The drug-containing system delivers sustained gemcitabine within the bladder for eligible patients with BCG-unresponsive disease.

What research teams should watch

Train urology staff on placement, scheduled removal, and safety precautions; keep cystoscopic surveillance and cystectomy referral on schedule.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

BCG-unresponsive non-muscle-invasive bladder cancer

PRIMARY RECORDS

Sources